Bioxytran Releases Details on a Novel Carbohydrate Galectin Inhibitor designed to Eliminate COVID-19 in Patients
Retrieved on:
Tuesday, March 31, 2020
Over the past decade there has been a strong body of evidence that indicates that Galectin-1 is implicated in viral pathogenesis.
Key Points:
- Over the past decade there has been a strong body of evidence that indicates that Galectin-1 is implicated in viral pathogenesis.
- This galectin-1 treatment resulted in a survival benefit of the mice and indicated theoretical mechanisms of action (MOA) in humans.
- The SARS virus has a galectin fold which in theory represents a binding spot on the virus for Bioxytrans galectin-1 inhibitor.
- The journal articles provide a strong foundation that galectin-1 is implicated in COVID-19, said CEO David Platt of Bioxytran Inc. and co-author of Galectin.